DO
PTCT icon

denkapparat Operations’s PTC Therapeutics PTCT Stock Holding History

denkapparat Operations’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Sell
3,290
-2,668
-45% -$189K 0.09% 309
2025
Q4 		$453K Hold
5,958
– – 0.25% 163
2025
Q3 		$366K Buy
+5,958
New +$310K 0.23% 169

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

denkapparat Operations's PTCT Position: Q1 2026 in Review

denkapparat Operations reduced its PTC Therapeutics (PTCT) stake by 45% in Q1 2026, selling an estimated $189K and leaving 3,290 shares worth $224K. The position accounts for 0.09% of the portfolio, ranked #309.

denkapparat Operations first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $453K in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • denkapparat Operations held 3,290 shares of PTC Therapeutics worth $224K as of Q1 2026.
  • denkapparat Operations sold 2,668 PTC Therapeutics shares in Q1 2026, an estimated $189K.
  • PTC Therapeutics made up 0.09% of denkapparat Operations's portfolio in Q1 2026, its #309 holding.
  • denkapparat Operations first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • denkapparat Operations's PTC Therapeutics position peaked at $453K in Q4 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on denkapparat Operations's 13F filing for Q1 2026, filed 11 May 2026.